Novavax’s vaccine might outperform mRNA vaccine against BA.5

FORTUNE 

by Grady McGregor / Jul 14, 2022 / 4:04 AM

For now, Novavax’s vaccine will only be available in the U.S. as a primary, two-dose regimen, meaning those who want a Novavax booster shot will likely have to wait several weeks or longer.

Novavax’s vaccine has been approved as both a primary vaccine and a booster in dozens of markets including in the European Union, Australia, and Japan. The company will soon seek authorization as a booster dose in the U.S. and is working on an Omicron-specific booster jab that it expects to roll out later this fall.

On July 1, Novavax said that its vaccine prompted “broad immune responses” against all COVID variants, including BA.5, in clinical data. Novavax has not publicly released the data, but some experts are optimistic that it might outperform mRNA vaccines against BA.5 due to its technology.

所有跟帖： 

• 等最后做出来了，可能病毒又变异了 -rancho2008- ♀ (0 bytes) () 07/14/2022 postreply 10:11:55

• 已经做出来了吧？ -dudaan- ♂ (0 bytes) () 07/14/2022 postreply 12:22:24

• 我说的是针对奥秘的疫苗现在还没出来 -rancho2008- ♀ (0 bytes) () 07/14/2022 postreply 14:00:59

• 感觉这些药厂就像《卖拐》里的赵本山，大多数人都被忽悠成了范伟 -红泥小火炉- ♂ (0 bytes) () 07/14/2022 postreply 14:32:10

• Novavax 声称其疫苗对所有 Omricron 变体均有效（见链接） -Ron47- ♂ (80 bytes) () 07/14/2022 postreply 15:53:02